An Overview of GLP-1 RAs for CV Risk Reduction in T2DM Patients

GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. This interactive infographic activity will walk you through these updates by using high-impact visuals to summarize the evidence, as well as added expert perspectives.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the mechanisms of action, different properties, as well as efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM.
  • Interpret the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk.
  • Review the recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk.
  • Develop individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk.
Course summary
Available credit: 
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
Course expires: 

Vanita R. Aroda, MD (Chair)
Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Dr. Aroda discloses the following: 

Consulting Fees: Applied Therapeutics, Duke, Novo Nordisk, Pfizer, Sanofi

Contracted Research: Applied Therapeutics/Medpace; Eli Lilly; Premier/Fractyl; Novo Nordisk; Sanofi/Medpace

Other: Spouse was/is an employee of Merck, Janssen, respectively


Darren G. McGuire, MD, MHSc
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Parkland Health and Hospital System
Dallas, TX

Dr. McGuire discloses the following: 

Consulting Fees: Lilly USA, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Applied Therapeutics, Metavant, Sanofi, Afimmune, Lexicon, CSL Behring, Bayer

Other: Honoraria for Trial Leadership: Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co., Pfizer, Novo Nordisk, Esperion, Lilly USA, Lexicon, CSL Behring


Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Adjunct
Professor of Medicine, Johns Hopkins University School of Medicine
Orlando, FL

Dr. Pratley discloses the following: 

Grants from Hanmi Pharmaceutical Co., Janssen

Consulting, speaker fees from Merck

Grants, speaker fees and consulting fees from Novo Nordisk

Consulting fees from Pfizer

Grants from Poxel SA

Grants and consulting fees from Sanofi

Consulting fees from Scohia Pharma Inc.

Consulting fees from Sun Pharmaceutical Industries

All honoraria directed toward a non-profit which supports education and research

1 hour

This activity is supported by an educational grant from Novo Nordisk.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. 

Postgraduate Institute for Medicine designates this continuing education activity for 1.0contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-099-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 1.0 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period April 6, 2022 through April 6, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.